vixencizumab

Vixencizumab (also known as Firsekibart) is a humanized monoclonal antibody that specifically targets and neutralizes **interleukin-1 beta (IL-1β)**. By binding to IL-1β, it prevents the cytokine from interacting with its receptor, thereby inhibiting the downstream inflammatory signaling pathways that drive various autoinflammatory and autoimmune conditions. The drug is primarily being developed by **InnoCare Pharma** for the treatment of IL-1β-driven rare autoinflammatory diseases, including **adult-onset Still's disease (AOSD)**, **cryopyrin-associated periodic syndrome (CAPS)**, **familial Mediterranean fever (FMF)**, and **Schnitzler syndrome**. Clinical evaluation in China includes basket studies assessing its safety, efficacy, and impact on inflammatory biomarkers in these patient populations.

Brand names

Firsekibart

Other names

vixencizumabFirsekibart